Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Specialty pharmaceutical company Mayne Pharma Group's products division has launched Doxycycline Hyclate Delayed-Release 75mg and 100mg tablets, in the US.
Subscribe to our email newsletter
Doxycycline Hyclate Delayed-Release Tablets, 75mg and 100mg are authorised generic versions of the Doryx 75mg and 100mg products respectively.
Doryx capsules and tablets are delayed release oral formulations of doxycycline (a tetracycline class of antibiotic), that can be used to treat certain types of infections, as adjunctive treatment of severe acne and as an anti-malarial.
Mayne Pharma CEO Scott Richards said, "We are very excited about the launch of these products which will be the first revenue synergies to materialise from the Metrics, Inc. acquisition completed in November 2012."
As per IMS Health data, the US sales of Doxycycline Hyclate Delayed-Release Tablets, 75mg and 100mg, were approximately $24m for the 12 months ending on 30 April 2013.